Richard Traynor

Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ.

Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ.

Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ.

Part of Certara, Inc., Certara UK Holdings Ltd. is a private company that develops drug therapies. The company is based in London, UK. Certara UK Holdings was founded in 2004.

LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America.

Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ.

Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ.

LifeCell Corp. develops and markets tissue repair products. The firm focuses on reconstructive, urogynecologic and orthopedic surgical procedures. Its products include alloderm, strattice, graft jacket, allocraftdbm and repliform. The company was founded in 1986 and is headquartered in Branchburg, NJ.

LifeCell Corp. develops and markets tissue repair products. The firm focuses on reconstructive, urogynecologic and orthopedic surgical procedures. Its products include alloderm, strattice, graft jacket, allocraftdbm and repliform. The company was founded in 1986 and is headquartered in Branchburg, NJ.

LifeCell Corp. develops and markets tissue repair products. The firm focuses on reconstructive, urogynecologic and orthopedic surgical procedures. Its products include alloderm, strattice, graft jacket, allocraftdbm and repliform. The company was founded in 1986 and is headquartered in Branchburg, NJ.

Part of Certara, Inc., Certara UK Holdings Ltd. is a private company that develops drug therapies. The company is based in London, UK. Certara UK Holdings was founded in 2004.

Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ.

LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America.